{
    "name": "iohexol",
    "comment": "Rx",
    "other_names": [
        "Omnipaque",
        "Oraltag"
    ],
    "classes": [
        "Iodinated Contrast Media"
    ],
    "source": "https://reference.medscape.com/drug/omnipaque-oraltag-iohexol-343760",
    "pregnancy": {
        "common": [
            "Postmarketing data with use in pregnant women are insufficient to determine if there is drug-associated risk of adverse developmental outcomes; drug crosses placenta and reaches fetal tissues in small amounts; in animal reproduction studies, no adverse developmental effects were observed following intravenous administration to pregnant rats and rabbits during organogenesis at doses up to 0.4 (rat) and 0.5 (rabbit) times maximum recommended human intravenous dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": []
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "For procedural contraindications see package insert",
                "Intrathecal administration of OMNIPAQUE 140 and OMNIPAQUE 350",
                "Parenteral administration of OMNIPAQUE oral solution 9 and 12",
                "Significant bacterial infection"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "DO NOT immediately repeat myelography because of technical problem (see Dosing)",
                "Inhibits blood coagulation",
                "Caution in combined renal/hepatic disease, severe multiple myeloma, anuria, CHF, severe arterial/venous disease",
                "Hypertensive crisis has occurred after use of iodinated contrast agents in patient with pheochromocytoma; monitor patients when administering intravascularly if pheochromocytoma or catecholamine-secreting paragangliomas are suspected; inject minimum amount of contrast necessary, assess blood pressure throughout procedure, and have measures for treatment of a hypertensive crisis readily available",
                "Iodinated contrast agents when administered intravascularly may promote sickling in individuals who are homozygous for sickle cell disease; hydrate patients prior to and following administration and administer only if the necessary imaging information cannot be obtained with alternative imaging modalities",
                "Focal and generalized motor seizures reported patients with history of epilepsy when higher than recommended doses used",
                "If immediate, transient pain occurs during hysterosalpingography, monitor injection pressure and volume instilled to minimize pain and to avoid disruptive distention of uterus and fallopian tubes; fluoroscopic monitoring recommended ",
                "Acute renal failure reported in diabetic patients with diabetic nephropathy and in susceptible nondiabetic patients (often elderly with preexisting renal disease) following excretory urography; careful consideration of potential risks should be given before performing radiographic procedures in these patients",
                "Extravasation during intravascular injection may cause tissue necrosis and/or compartment syndrome, particularly in patients with severe arterial or venous disease; ensure intravascular placement of catheters prior to injection; monitor patients for extravasation and advise patients to seek medical care for progression of symptoms",
                "Oraltag not a sterile product and not suitable for a parenteral route of administration; serious adverse reactions such as sepsis can occur if administered parenterally; do not administer solution parenterally",
                "Thyroid storm has occurred after intravascular use of iodinated contrast agents in patients with hyperthyroidism, or with autonomously functioning thyroid nodule; evaluate risk in such patients before use",
                "Iodinated contrast agents may alter results of thyroid function tests which depend on iodine estimation, eg, radioactive iodine uptake test; therefore, such testing, if indicated, should be performed prior to administration of this preparation"
            ],
            "specific": [
                {
                    "type": "Thyroid dysfunction in pediatric patients",
                    "description": [
                        "Thyroid dysfunction characterized by hypothyroidism or transient thyroid suppression reported after both single exposure and multiple exposures to iodinated contrast media; among patients 0- 3 years of age exposed to iodinated contrast media, thyroid dysfunction reported depending on age of patient and dose of the iodinated contrast agent",
                        "Pediatric patients with congenital cardiac conditions may be at greatest risk given that they often require high doses of contrast during invasive cardiac procedures",
                        "An underactive thyroid during early life may be harmful for cognitive and neurological development and may require thyroid hormone replacement therapy",
                        "After exposure to iodinated contrast media, individualize thyroid function monitoring in pediatric patients 0-3 years of age based on underlying risk factors, especially in term and preterm neonates",
                        "Pediatric patients 0-3 years of age warrant closer monitoring because an underactive thyroid during early life may be harmful to motor, hearing, and cognitive development and may require transient T4 replacement therapy"
                    ]
                },
                {
                    "type": "Contrast induce acute kidney injury",
                    "description": [
                        "Acute kidney injury, including renal failure, may occur after parenteral administration; risk factors include: preÂ­existing renal impairment, dehydration, diabetes mellitus, congestive heart failure, advanced vascular disease, elderly age, concomitant use of nephrotoxic or diuretic medications, multiple myeloma / paraproteinaceous diseases, repetitive and/or large doses of an iodinated contrast agent",
                        "Use lowest necessary dose in patients with renal impairment; adequately hydrate patients prior to and following parenteral administration; do not use laxatives, diuretics, or preparatory dehydration prior to administration"
                    ]
                },
                {
                    "type": "Cardiovascular adverse reactions",
                    "description": [
                        "Life-threatening or fatal cardiovascular reactions including hypotension, shock, cardiac arrest have occurred with parenteral administration; most deaths occur during injection or five to ten minutes later, with cardiovascular disease as the main aggravating factor; cardiac decompensation, serious arrhythmias, and myocardial ischemia or infarction can occur during coronary arteriography and ventriculography",
                        "Based upon clinical literature reported deaths from administration of iodinated contrast agents range from 6.6 per million (0.00066%) to 1 in 10,000 (0.01%); use lowest necessary dose in patients with congestive heart failure and always have emergency resuscitation equipment and trained personnel available; monitor all patients for severe cardiovascular reaction"
                    ]
                },
                {
                    "type": "Thromboembolic events",
                    "description": [
                        "Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke can occur during angiocardiography procedures with both ionic and nonionic contrast media; during these procedures, increased thrombosis and activation of the complement system occurs",
                        "Risk factors for thromboembolic events include length of procedure, catheter and syringe material, underlying disease state, and concomitant medications; to minimize thromboembolic events, use meticulous angiographic techniques, and minimize length of the procedure",
                        "Avoid blood remaining in contact with syringes containing iodinated contrast agents, which increases risk of clotting; avoid angiocardiography in patients with homocystinuria because of risk of inducing thrombosis and embolism"
                    ]
                },
                {
                    "type": "Hypersensitivity reactions",
                    "description": [
                        "Therapy can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis; manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock; most severe reactions develop shortly after start of injection (within3 minutes), but reactions can occur up to hours later",
                        "There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (eg, bronchial asthma, drug, or food allergies) or other hypersensitivities",
                        "Premedication with antihistaminesor corticosteroids does not prevent serious life-threatening reactions, but may reduce both their incidence and severity",
                        "Obtain a history of allergy, hypersensitivity, or hypersensitivity reactions to iodinated contrast agents and always have emergency resuscitation equipment and trained personnel available prior to administration; monitor all patients for hypersensitivity reactions"
                    ]
                },
                {
                    "type": "Severe cutaneous adverse reactions",
                    "description": [
                        "Severe cutaneous adverse reactions (SCAR) may develop from 1 hour to several weeks after intravascular contrast agent administration",
                        "These reactions include Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN), acute generalized exanthematous pustulosis (AGEP), and drug reaction with eosinophilia and systemic symptoms (DRESS)",
                        "Reaction severity may increase and time to onset may decrease with repeat administration of contrast agents; prophylactic medications may not prevent or mitigate severe cutaneous adverse reactions",
                        "Avoid administering to patients with a history of a severe cutaneous adverse reaction to this drug"
                    ]
                }
            ]
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Nervous system disorders",
            "percent": "49"
        },
        {
            "name": "Meningism",
            "percent": "3"
        },
        {
            "name": "aseptic meningitis",
            "percent": "3"
        },
        {
            "name": "seizures or status epilepticus",
            "percent": null
        },
        {
            "name": "disorientation",
            "percent": null
        },
        {
            "name": "coma",
            "percent": null
        },
        {
            "name": "depressed or loss of consciousness",
            "percent": null
        },
        {
            "name": "transient contrast",
            "percent": null
        },
        {
            "name": "induced toxic encephalopathy",
            "percent": null
        },
        {
            "name": "including amnesia",
            "percent": null
        },
        {
            "name": "hallucination",
            "percent": null
        },
        {
            "name": "paralysis",
            "percent": null
        },
        {
            "name": "paresis",
            "percent": null
        },
        {
            "name": "speech disorder",
            "percent": null
        },
        {
            "name": "aphasia",
            "percent": null
        },
        {
            "name": "dysarthria",
            "percent": null
        },
        {
            "name": "restlessness",
            "percent": null
        },
        {
            "name": "tremors",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "muscle spasms or spasticity",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Confusional state",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "anxiety",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Transient visual impairment including cortical blindness",
            "percent": null
        },
        {
            "name": "Renal reactions",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "Cardiovascular disorders",
            "percent": null
        },
        {
            "name": "Severe cardiac complications",
            "percent": null
        },
        {
            "name": "including cardiac arrest",
            "percent": null
        },
        {
            "name": "cardiopulmonary arrest",
            "percent": null
        },
        {
            "name": "shock",
            "percent": null
        },
        {
            "name": "peripheral vasodilatation",
            "percent": null
        },
        {
            "name": "palpitations",
            "percent": null
        },
        {
            "name": "vasospasm including spasm of coronary arteries",
            "percent": null
        },
        {
            "name": "myocardial infarction",
            "percent": null
        },
        {
            "name": "syncope",
            "percent": null
        },
        {
            "name": "cyanosis",
            "percent": null
        },
        {
            "name": "pallor",
            "percent": null
        },
        {
            "name": "flushing",
            "percent": null
        },
        {
            "name": "chest pain",
            "percent": null
        },
        {
            "name": "Hemodynamic reactions",
            "percent": null
        },
        {
            "name": "Vasospasm and thrombophlebitis following intravenous injection",
            "percent": null
        },
        {
            "name": "Blood and lymphatic system disorders",
            "percent": null
        },
        {
            "name": "Neutropenia",
            "percent": null
        },
        {
            "name": "Nervous system disorders",
            "percent": null
        },
        {
            "name": "Disorientation",
            "percent": null
        },
        {
            "name": "coma",
            "percent": null
        },
        {
            "name": "depressed or loss of consciousness",
            "percent": null
        },
        {
            "name": "transient contrast",
            "percent": null
        },
        {
            "name": "induced toxic encephalopathy",
            "percent": null
        },
        {
            "name": "including amnesia",
            "percent": null
        },
        {
            "name": "hallucination",
            "percent": null
        },
        {
            "name": "paralysis",
            "percent": null
        },
        {
            "name": "paresis",
            "percent": null
        },
        {
            "name": "speech disorder",
            "percent": null
        },
        {
            "name": "aphasia",
            "percent": null
        },
        {
            "name": "dysarthria",
            "percent": null
        },
        {
            "name": "restlessness",
            "percent": null
        },
        {
            "name": "tremors",
            "percent": null
        },
        {
            "name": "hypoesthesia",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Confusional state",
            "percent": null
        },
        {
            "name": "agitation",
            "percent": null
        },
        {
            "name": "Eye disorders",
            "percent": null
        },
        {
            "name": "Eye irritation or itchiness",
            "percent": null
        },
        {
            "name": "periorbital edema",
            "percent": null
        },
        {
            "name": "ocular or conjunctival hyperemia",
            "percent": null
        },
        {
            "name": "lacrimation",
            "percent": null
        },
        {
            "name": "Renal reactions",
            "percent": null
        },
        {
            "name": "Acute kidney injury",
            "percent": null
        },
        {
            "name": "nephropathy toxic",
            "percent": null
        },
        {
            "name": "CIN",
            "percent": null
        },
        {
            "name": "transient proteinuria",
            "percent": null
        },
        {
            "name": "oliguria or anuria",
            "percent": null
        },
        {
            "name": "increased serum creatinine",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Abdominal pain",
            "percent": null
        },
        {
            "name": "pancreatitis aggravated",
            "percent": null
        },
        {
            "name": "salivary gland enlargement",
            "percent": null
        },
        {
            "name": "Immediate",
            "percent": null
        },
        {
            "name": "transient pain",
            "percent": null
        },
        {
            "name": "Nervous system",
            "percent": null
        },
        {
            "name": "Pain",
            "percent": null
        },
        {
            "name": "somnolence and fever each with an individual incidence of",
            "percent": null
        },
        {
            "name": "Gastrointestinal system",
            "percent": null
        },
        {
            "name": "Nausea",
            "percent": null
        }
    ]
}